Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
NCT ID: NCT00764387
Last Updated: 2014-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
166 participants
INTERVENTIONAL
2008-03-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Gadovist® (Gadobutrol, BAY86-4875)
0,1 mmol/kg of body weight in the vein, single administration
Arm 2
Dotarem
0,1 mmol/kg of body weight in the vein, single administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gadovist® (Gadobutrol, BAY86-4875)
0,1 mmol/kg of body weight in the vein, single administration
Dotarem
0,1 mmol/kg of body weight in the vein, single administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Andria, Bari, Italy
Catania, , Italy
Chieti, , Italy
Messina, , Italy
Milan, , Italy
Napoli, , Italy
Novara, , Italy
Roma, , Italy
Roma, , Italy
Siena, , Italy
Trieste, , Italy
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here and search for Bayer Product information provided by EMA
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-005693-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
312021
Identifier Type: OTHER
Identifier Source: secondary_id
91780
Identifier Type: -
Identifier Source: org_study_id